Abstract
Summary
There are several treatment options available for patients who have mild persistent asthma. After being shown a typical case study and three possible treatment options, three respiratory specialists each selected a different option. The options were: using a combination beclometasone/albuterol inhaler on an as-needed basis; daily treatment with an oral leukotriene receptor antagonist together with as-needed use of a short-acting beta2-agonist (SABA) inhaler; and using a combination inhaled corticosteroid/long-acting beta2-agonist inhaler once-daily together with as-needed SABA. The evidence for each option is reviewed in the light of recent research.
Article PDF
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr. Kaplan has served as an advisor or speaker for Altana, Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline. Janssen Ortho, Merck Frosst, Novartis, Pfizer, Purdue, and Ross
Rights and permissions
About this article
Cite this article
Kaplan, A. Treatment of mild persistent asthma. Prim Care Respir J 17, 251–252 (2008). https://doi.org/10.3132/pcrj.2008.00006
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3132/pcrj.2008.00006